SML2166
KML29
≥98% (HPLC)
别名:
1,1,1,3,3,3-Hexafluoropropan-2-yl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate, 4-[bis(1,3-Benzodioxol-5-yl)hydroxymethyl]-1-piperidinecarboxylic acid 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ester, KML 29, KML-29
并加购，请在购物车里查看协议价、货期和发货地。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C24H21F6NO7
化学文摘社编号:
分子量:
549.42
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
FC(F)(F)C(OC(=O)N1CCC(CC1)C(O)(c4cc5c(cc4)OCO5)c2cc3c(cc2)OCO3)C(F)(F)F
InChI
1S/C24H21F6NO7/c25-23(26,27)20(24(28,29)30)38-21(32)31-7-5-13(6-8-31)22(33,14-1-3-16-18(9-14)36-11-34-16)15-2-4-17-19(10-15)37-12-35-17/h1-4,9-10,13,20,33H,5-8,11-12H2
InChI key
SXHQLPHDBLTFPM-UHFFFAOYSA-N
Biochem/physiol Actions
KML29, an O-hexafluoroisopropyl (HFIP) carbamate analogue of JZL184. is a potent and orally active monoacylglycerol lipase (monoglyceride lipase; MAGL; MGLL; MGL) inhibitor (IC50 = 5.9/15/43 nM against human/mouse/rat MAGL) that targets MAGL active site with greatly improved selectivity (rat/mouse ABHD6 IC50 = 1.60/4.87; no inhibitory activity against human/rat/mouse fatty acid amide hydrolase (FAAH) up to 50 μM). KML29 in vivo treatment results in a selective upregulation of 2-arachidonoyl glycerol (2-AG), but not N-arachidonoyl-ethanolamine (AEA) in mice (brain Emax ∼20 mg/kg p.o. or i.p.; peripheral Emax ∼1 mg/kg p.o.) and rats (brain Emax ∼40 mg/kg i.p.). KML29 reduces inflammatory and neuropathic nociceptive behaviour in animal studies without cannabimimetic side effects seen with dual FAAH & MAGL inhibition, chronic administration, however, leads to CB1 receptor desensitization as observed with other MAGL inhibitors.
Orally active, potent and highly selective monoacylglycerol lipase (MAGL) inhibitor with in vivo analgesic efficacy without cannabimimetic side effects.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable